iX Biopharma of Singapore struck a deal for China commercialization of its sublingual wafer version of sidenafil, an erectile dysfunction treatment. The product, Wafesil, is formulated using iX Biopharma’s patented sublingual drug delivery technology. China Resources Pharmaceutical Commercial Company, which signed a broad China commercialization deal with iX earlier this year, will market and distribute the drug. iX will be responsible for China approvals of the product, while China Resources will make upfront and licensing payments to iX. The product, Wafesil, is approved for use in Australia . More details.... Share this with colleagues: // //